Video

New superbug reaches the U.S.

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures


Researchers have found a person in the United States carrying bacteria resistant to antibiotics of last resort, according to an article on The Washington Post website.

Researchers worry that its colistin-resistance gene, known as mcr-1, could spread to other bacteria that can already evade other antibiotics.

Colistin is the antibiotic of last resort for particularly dangerous types of superbugs, including CRE, which health officials call a “nightmare bacteria.” 

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures.

Read the article.

 



June 7, 2016


Topic Area: Industry News


Recent Posts

How Architects Shape the Future of Healthcare Facilities

Healthcare architecture is more than just designing and building hospitals.


UNC Health, Duke Health Form Partnership for Stand-alone Children's Hospital

The partners plan to break ground together on the new NC Children’s campus by 2027.


Sarasota Memorial Hospital Plans to Build New Facility in North Port

The six-story, 100-bed hospital is slated to open in fall of 2028.


CMMS, Data and the Path to Compliance

Taking control of healthcare facilities data in CMMS enables managers to use it to ensure the efficient operation and maintenance of their assets.


Healthcare is a Major Ransomware Target

Healthcare is the third-most-targeted sector, according to the report.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.